Evidence map›Paper›PMID 37085808›Full record

ReviewEnvironmental health : a global access science source2023

Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA's criteria.

Laura N Vandenberg, R Thomas Zoeller, Gail S Prins, Leonardo Trasande

Abstract readReview
In one paragraph

Review in Environmental health : a global access science source, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura N VandenbergDepartment of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts - Amherst, 240G Goessmann, 686 N. Pleasant Street, Amherst, MA, 01003, USA. lvandenberg@schoolph.umass.edu.ORCID 0000-0002-6807-9136
R Thomas ZoellerDepartment of Biology, University of Massachusetts Amherst, Amherst, MA, USA.
Gail S PrinsDepartment of Urology, School of Medicine, Division of Epidemiology & Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, USA.
Leonardo TrasandeDepartments of Pediatrics, Environmental Medicine, and Population Health, New York University School of Medicine, New York, NY, USA.

Funding

Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

backgroundIn the US, the Food and Drug Administration (US FDA) is charged with protecting the safety of food from both pathogens and chemicals used in food production and food packaging. To protect the public in a transparent manner, the FDA needs to have an operational definition of what it considers to be an "adverse effect" so that it can take action against harmful agents. The FDA has recently published two statements where, for the first time, it defines the characteristics of an adverse effect that it uses to interpret toxicity studies.

objectiveIn this brief review, we examine two recent actions by the FDA, a proposed rule regarding a color additive used in vegetarian burgers and a decision not to recall fish with high levels of scombrotoxin. We evaluated the FDA's description of the criteria used to determine which outcomes should be considered adverse. OVERVIEW: We describe three reasons why the FDA's criteria for "adverse effects" is not public health protective. These include an unscientific requirement for a monotonic dose response, which conflates hazard assessment and dose response assessment while also ignoring evidence for non-linear and non-monotonic effects for many environmental agents; a requirement that the effect be observed in both sexes, which fails to acknowledge the many sex- and gender-specific effects on physiology, disease incidence and severity, and anatomy; and a requirement that the effects are irreversible, which does not acknowledge the role of exposure timing or appreciate transgenerational effects that have been demonstrated for environmental chemicals.

conclusionsThe FDA's criteria for identifying adverse effects are inadequate because they are not science-based. Addressing this is important, because the acknowledgement of adverse effects is central to regulatory decisions and the protection of public health.

Indexed as

Food SafetyUnited StatesUnited States Food and Drug AdministrationEndocrine disrupting chemicalGender differenceHazard assessmentLupronPharmaceuticalTransparency

Identifiers

PMID37085808
PMCPMC10120250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.